Meloxicam Tablet
Product Images NDC 71335-3194

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 71335-3194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table1a (Table1a)

A data table presenting adverse event percentages occurring in 2% or more of Meloxicam patients over a 12-week osteoarthritis trial comparing placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily. The table categorizes events by system (gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin) with specific events listed under each category and corresponding percentages for each treatment group.*

FDA Label Image

Table1b (Table1b)

Table showing adverse events occurring in 2% or more of patients treated with Meloxicam 7.5 mg daily and 15 mg daily compared to placebo in two 12-week rheumatoid arthritis placebo-controlled trials. Categories include gastrointestinal disorders, general disorders, infections, musculoskeletal, nervous system, and skin disorders, with percentage frequencies for each group.*

FDA Label Image

Table2 (Table2)

A data table presenting adverse events occurring in 2% or more of Meloxicam patients from 4 to 6 weeks and 6 month active-controlled osteoarthritis trials. It compares the percentage of various side effects by category including gastrointestinal, body as a whole, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary issues for Meloxicam 7.5 mg and 15 mg daily doses.*

FDA Label Image

Bodywhole (Body Whole)

A table listing adverse reactions for Meloxicam organized by body system. It includes reactions such as allergic reactions, cardiovascular events, nervous system effects, gastrointestinal issues, heart rhythm disturbances, hematologic abnormalities, liver enzyme increases, dehydration, psychiatric symptoms, respiratory conditions, skin reactions, special senses impairment, and urinary system effects.*

FDA Label Image

Chemical Structure (Meloxicam Str)

Chemical structure of Meloxicam, showing its molecular components including aromatic rings, sulfonamide group, and heterocyclic thiazole ring with various functional groups attached.*

FDA Label Image

Table4 (Table4)

A data table presenting pharmacokinetic parameters for oral Meloxicam at 7.5 mg and 15 mg doses under various conditions, including healthy male adults, elderly males and females (fed), and patients with renal failure or hepatic insufficiency (fasted). Parameters shown include Cmax, tmax, t1/2, CL/f, and Vz/f, alongside subject counts and study notes.*

FDA Label Image

Logo (Logo)

FDA Label Image

Label (Lbl713353194)

Label for Meloxicam Tablet USP 15 mg, oral tablets in a package of 30. The label includes storage instructions, child-resistant packaging notice, and QR code for full prescribing information. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Macleods Pharmaceuticals Ltd. Includes NDC 71335-3194-1 and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.